Showing results (1221-1230 of 1,708) with videos related to
Sort By:
Pageof 171
European Heart Journal|August 26, 2023
Heart failure medical therapy prior to mitral transcatheter edge-to-edge repair: the STS/ACC Transcatheter Valve Therapy RegistryAnubodh S Varshney, Miloni Shah, Sreekanth Vemulapalli, et al.European Journal of Preventive Cardiology|October 17, 2019
Risk factors and clinical outcomes in chronic coronary and peripheral artery disease: An analysis of the randomized, double-blind COMPASS trialThomas Vanassche, Peter Verhamme, Sonia S Anand, et al.American Heart Journal|December 5, 2016
Bleeding risk following percutaneous coronary intervention in patients with diabetes prescribed dual anti-platelet therapyAnna Grodzinsky, Suzanne V Arnold, Tracy Y Wang, et al.American Heart Journal|May 22, 2012
Rationale and design of the Cangrelor versus standard therapy to acHieve optimal Management of Platelet InhibitiON PHOENIX trialSergio Leonardi, Kenneth W Mahaffey, Harvey D White, et al.JACC. Cardiovascular Interventions|April 7, 2021
Evaluation of Dual Versus Triple Therapy by Landmark Analysis in the RE-DUAL PCI TrialBenjamin E Peterson, Deepak L Bhatt, Ph Gabriel Steg, et al.JACC. Cardiovascular Interventions|April 18, 2016
Percutaneous Coronary Intervention in Native Coronary Arteries Versus Bypass Grafts in Patients With Prior Coronary Artery Bypass Graft Surgery: Insights From the Veterans Affairs Clinical Assessment, Reporting, and Tracking ProgramEmmanouil S Brilakis, Colin I O'Donnell, William Penny, et al.Journal of the American College of Cardiology|April 28, 2022
The National Cardiovascular Data Registry Data Quality Program 2020: JACC State-of-the-Art ReviewDavid J Malenka, Deepak L Bhatt, Steven M Bradley, et al.The Lancet. Diabetes & Endocrinology|April 4, 2022
Metabolic risk factors and effect of alirocumab on cardiovascular events after acute coronary syndrome: a post-hoc analysis of the ODYSSEY OUTCOMES randomised controlled trialPetr Ostadal, Philippe Gabriel Steg, Yann Poulouin, et al.International Journal of Cardiology|December 20, 2018
Characteristics and outcomes of patients requiring bailout use of glycoprotein IIb/IIIa inhibitors for thrombotic complications of percutaneous coronary intervention: An analysis from the CHAMPION PHOENIX trialJeremie Abtan, Gregory Ducrocq, Ph Gabriel Steg, et al.International Journal of Cardiology|May 17, 2021
Results of an international crowdsourcing survey on the treatment of non-ST segment elevation ACS patients at high-bleeding risk undergoing percutaneous interventionDeepak L Bhatt, Juan Carlos Kaski, Sean Delaney, et al.Pageof 171